ABSTRACT Human malignant T cell lines have high levels of deoxyribonucleoside phosphorylating activity and low levels of deoxyribonucleotide dephosphorylating activity. When incubated with deoxyadenosine or thymidine, the malignant T cell lines rapidly accumulate toxic concentrations of dATP and dTlTlP, respectively. This unusual pattern of deoxyribonucleotide metabolism renders the malignant T cells especially vulnerable to the toxic effects of deoxyribonucleosides and related analogues.
Inherited deficiencies of the purine metabolic enzymes adenosine deaminase (adenosine aminohydrolase, EC 3.5.4.4) and purine-nucleoside phosphorylase (purine-nucleoside:orthophosphate ribosyltransferase, EC 2.4.2.1) selectively interfere with the growth and development of the human lymphoid system (1, 2) . In all phosphorylase-deficient patients, and some deaminase-deficient patients, T lymphocytes and cellular immune functions are more severely affected than are B lymphocytes and humoral immune responses (1) (2) (3) .
We have proposed that lymphospecific toxicity in deaminase and phosphorylase deficiencies might result from the selective phosphorylation and "trapping" by T lymphocytes of the deaminase substrate deoxyadenosine and the phosphorylase substrate deoxyguanosine, mediated by lymphospecific deoxyribonucleoside kinase(s), with the subsequent formation of toxic deoxyribonucleoside triphosphates (4) . This hypothesis was difficult to test in vivo because of the severe lymphopenia observed in untreated enzyme-deficient patients. In an effort to find a relevant in vitro model system, we therefore turned to human malignant T lymphoblasts, which are conveniently available as continuous cell lines and share certain antigenic and biochemical characteristics with primitive thymocytes (5) (6) (7) (8) . Initial studies showed that the malignant T cell lines were far more sensitive than human B cell lines to the growth inhibitory effects of deoxyadenosine, deoxyguanosine, 9-4-D-arabinofuranosyladenine, and thymidine (9) . The differential sensitivity of the T and B cell lines to deoxyadenosine toxicity could not be attributed solely to the relative amounts of deoxyadenosine phosphorylating activity in cell extracts, but did correlate with the ability of the whole cells to accumulate dATP (9, 10 oxycoformycin, and 300 ,uM dATP, dGTP, or dTTP containing 1 yCi (1 Ci = 3.7 X 1010 becquerels) of tritiated nucIoi (ICN) in a final volume of 50 ,ul. After 30 min at 370C for the B cells and 120 min for the T cells, the reaction was terminated in a boiling water bath, insoluble material was removed by centrifugation, and 20 Ml of supernatant was spotted on PEIcellulose thin-layer chromatography sheets (EM Laboratories, Elmsford, NY). Nucleotides were separated from the bases and nucleosides by elution with methanol/water (1:1). The latter two spots were visualized by ultraviolet light, cut out, and assayed for radioactivity in a liquid scintillation counter. In some cases the specific 5'-nucleotidase inhibitor adenosine 5'-(a,i-methylene)diphosphate [AMP(CH2)P, P-L Biochemicals] was included in the reaction mixture (15) .
Nucleotidase Assay. 5'-Nucleotidase was assayed in intact or frozen-thawed cells at a density of 1.5-3.0 X 106 cells per ml in a buffer containing 8.6 mM magnesium chloride, 50 mM Tris-HCI at pH 6.9, and 215 MM [8-14C] inosine monophosphate (specific activity 6 mCi/mmol, Amersham/Searle) in a final volume of 35 ,l, either with or without 2.86 mM AMP(CH2)P.
After 15-60 min at 37°C the reaction was terminated by the addition of 5 ,ul of 8 M perchloric acid, and the products inosine and hypoxanthine were separated from inosine monophosphate by thin-layer chromatography as described above. Activities are expressed as pmol of product (inosine + hypoxanthine)/min per 106 cells. RESULTS Formation of dATP and dTTP by T and B Cell Lines. of cell viability. When dTTP levels were measured at 3 hr, the malignant T cells accumulated more triphosphate than the B cells over a wide range of thymidine concentrations (Fig. 3) .
Breakdown of Deoxyribonucleoside Triphosphates by T and B Cells. When the T cell line CCRF-CEM and the B cell line 894 were incubated in deoxyadenosine and then washed and placed in fresh medium, initial dATP levels rapidly decayed in the B cells but not the T cells (Fig. 4) . Moreover, broken cell preparations of all three T cell lines converted dATP, dGTP, and dTTP to nucleosides and bases at one-sixth the rate found in the three B cell lines tested ( Table 1 ). The breakdown of dATP by the B cells was reduced to 54% by 40 MM and to 24% by 300 ,M AMP(CH2)P, a specific 5'-nucleotidase inhibitor. Other experiments using [8-'4C] inosine monophosphate as substrate showed that the B cell lines indeed have manyfold higher levels of 5'-nucleotidase than the malignant T cell lines, although the activity varied considerably from one B cell line to another (Table 2 ). Less than 10% of the inosine monophosphate dephosphorylating activity assayed in whole or broken T cells at neutral pH, but greater-than 80% in the B cells, was AMP(CH2)P inhibitable. 
DISCUSSION
The present experiments have shown that three neoplastic human T cell lines break down deoxyribonucleoside triphosphates at a much slower rate than most B cell lines. In addition, the T lymphoblasts have much lower levels of 5'-nucleotidase than the B lymphoblasts do. The exact relationship between plasma membrane-associated 5'-nucleotidase and intracellular nucleotide breakdown is undefined. In any case, the low deoxyribonucleotide dephosphorylating activity of the malignant T cell lines, combined with the high deoxyadenosine phosphorylating activity previously observed, may explain the marked accumulation of dATP by T cells incubated with deoxyadenosine (4, 9). Because deoxyadenosine phosphorylating activity differs by not more than 3-fold in T and B cell extracts (9) , it is probably the rate of deoxyribonucleotide breakdown rather than formation that governs the differential ability of these cells to accumulate dATP. In support of this notion, although the T and B cell lines do not have significantly different levels of thymidine kinase (9) , the inability of the T cells to adequately break down thymidine nucleotides is also associated with the accumulation of dTTP by T cells incubated with thymidine. Foley and coworkers (16, 17) have shown that the malignant T cell line CCRF-CEM was manyfold more sensitive to thymidine toxicity than a wide variety of nonlymphoid cell lines derived from both normal and malignant cells. It is therefore also likely that the malignant T cell pattern of deoxyribonucleotide metabolism is uncommonly found among other nonlymphoid cell types. To three T cell and three B cell lines at densities of 1.5-3.0 X 106 cells per ml in a buffer containing 8.6 mM magnesium chloride and 50 mM Tris.HCl at pH 6.9 was added 215 ,gM [8-14C] The enzyme activities found in the neoplastic T cell linesi.e., high deaminase, high deoxycytidine kinase, and low 5'-nucleotidase-are similar to the enzyme activities previously measured in normal human thymocytes (4, (18) (19) (20) . Peripheral blood T cells, too, have lower 5'-nucleotidase activities than peripheral B cells (21) . However, 5'-nucleotidase activities are markedly depressed in approximately 70% of patients with B cell chronic lymphatic leukemia (22) . Furthermore, Allan and Crumpton have suggested that 5'-nucleotidase levels may differ among cortical and medullary thymocytes (20) . It is theoretically possible, therefore, that 5'-nucleotidase activities may vary during the development of both T and B lymphocyte populations.
The need for an accurate in vitro predictive test of the chemotherapeutic susceptibility of human tumor cells has long been recognized. Such information would be beneficial in designing an effective in vivo chemotherapeutic program (23). Ohnuma and coworkers (24) have shown that the sensitivity of human malignant cell lines in vitro to L-asparagine deprivation correlates with the effectiveness of L-asparaginase in treating acute leukemia. The marked sensitivity of human T lymphoblasts to deoxyribonucleoside toxicity, and their unusual enzymatic profile as demonstrated here, parallels and in part explains the T cell dysfunction seen in deaminase and phosphorylase deficiencies (25) (26) (27) (28) . With the above knowledge, one would predict that those human T cell-derived leukemias with high deoxyribonucleoside phosphorylating activities and low activities of 5'-nucleotidase might be effectively treated by deoxyribonucleosides and related analogues.
